QUality of life and Economic evaluation after neuroSTimulation for Epilepsy (QUESTE) in adolescents and adults with drug-resistant epilepsy: protocol for a multicentre, prospective observational cohort study in The Netherlands

• Published in: BMJ open Vol. 13; no. 6; p. e071575
• Main Authors: Smeets, Jacco J A S, Rijkers, Kim, Ackermans, Linda, Schijns, Olaf, van Mastrigt, Ghislaine A P G, Rouhl, Rob, Wagner, G Louis, van Kuijk, Sander, Nelissen, Jeske, van Straaten, Ilse E C W, Kho, Kuan, Snoeijen-Schouwenaars, Francesca, Meppelink, Anne-Marthe, Klinkenberg, Sylvia, Majoie, H J M
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 06-06-2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Protocol
• Subjects: Cohort analysis; Convulsions & seizures; Costs; Deep brain stimulation; Drug resistance; Epilepsy; Health care policy; health economics; Hospitals; Hypotheses; Neurology; Observational studies; Patients; Productivity; Quality of life; Questionnaires; Surgery; Systematic review; Teenagers; Netherlands; epilepsy; quality of life; health economics
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2023-071575

IntroductionEpilepsy is one of the most common chronic neurological disorders. Antiseizure medication (ASM) is the first choice of treatment, however, 30% of epilepsy patients are drug-resistant. For these patients, neuromodulation can be an option, especially when epilepsy surgery is not possible or did not lead to seizure freedom. Epilepsy is associated with reduced quality of life (QoL), which heavily depends on seizure control.The most recent Cochrane reviews have shown that vagus nerve stimulation and deep brain stimulation of the anterior nucleus of the thalamus, lead to a responder rate OR of, respectively, 1.93 and 1.20. The question arises if neuromodulation for drug-resistant epilepsy (DRE) will be more cost-effective than sole treatment with ASM. The current study aims to determine the change in QoL after neuromodulation. Secondarily, we will aim to study the cost-effectiveness of these treatments.Methods and analysisThis prospective cohort study aims at including 100 patients aged 16 or above who will be referred for neuromodulation, from January 2021 to January 2026. After informed consent, QoL and other relevant parameters will be assessed at baseline, 6 months, 1, 2 and 5 years after surgery. Data on seizure frequency will be derived from patient charts. We expect that DRE patients will report better QoL after neuromodulation. Even if they would still report seizures, the treatment can be seen as useful. This is especially true when patients can participate in society again to a greater extent than before treatment.Ethics and disseminationThe board of directors of participating centres all gave permission for this study to commence. The medical ethics committees decided that this study does not fall under the Medical Research Involving Human Subjects Act (WMO). The findings of this study will be presented at (inter)national conferences and in peer-reviewed journals.Trial registration numberNL9033.